Here, Mario Scigliano, serialisation & automation manager, and Christian Ahlmark, associate director, sales & key account management, CordenPharma, discuss how a CDMO can help give companies a fighting chance to be globally serialisation compliant.
In this roundtable, four industry leaders from Symbiosis Pharmaceutical Services, Recipharm, Sterling Pharma Solutions and Idifarma, reveal their thoughts on what the ‘mega trends’ are in the current pharma landscape.
CPhI Worldwide has revealed the finding from part i of its fifth edition of the CPhI Annual Report, which show the trend towards the integration of pharmaceutical outsourcing continues but the rate of change remains unclear.
Here, Michael Merges, Catalent Biologics, and Brian Fahie, Biogen, discuss the growing need for partners who can provide niche technologies to accelerate development projects.
In this article Steve Lam, senior vice president and head of biologics, Patheon, looks at which choice is best when developing a biomanufacturing strategy.
As pressure to get drugs to the human clinical trial stage increases more companies are looking to outsource not only non-core functions but major areas of R&D. Here, Praveen C. Surana, ELC Group, examines outsourcing projects in more detail.
Contract development and manufacturing organisation (CDMO) that specialises in spray drying and capsule filling services, Micro-Sphere, is investing €19 million to expand its GMP manufacturing capabilities at its Swiss facility.
Focusing on the keys to success for contract drug manufacturers, Arnaud Sergent, Serge Hovsepian, Nohmie Ben Rekassa and Ben Faircloth from L.E.K. Consulting detail the differentiation strategies that have proven themselves in the marketplace
Erik Haeffler, vice president of manufacturing services, Recipharm, examines the challenges and opportunities for a CDMO in the landscape of serialisation that contract partners must overcome.
Strategic outsourcing is trending within the pharmaceutical industry with companies relying on trusted and preferred suppliers in an integrated supply model, notes Justin Schroeder, executive director at PCI Pharma Services
